2022_Sep_ConnectinPharma_Easyfairs_Geneva

advanced search
2022_Stevanato_Aidaptus_Leaderboard
Isabelle Delcroix
Strategy Director
Nemera

Is this your profile?

About

Profile information not available.
If you are the Author contact us to add your profile details here.

Contributions

PREFILLED SYRINGES
ADJUSTING & CONTROLLING INJECTION SPEED BY DESIGN: IMPACT ON PAIN PERCEPTION
Isabell Delcroix and Pascal Dugand describe a study of the multi-award-winning Safelia® auto-injector platform, which showed how varying and slowing injection speed could reduce pain perception.

More contributions

PREFILLED SYRINGES
COMPANY SHOWCASE: NEMERA (INJECTABLES OFFERING)
Nemera and its partners empower patients through good design with Nemera’s extensive experience in developing and manufacturing parenteral drug delivery devices. Its global centre of expertise comprises more than 60 engineers and experts in creative design and human factors activities.
PREFILLED SYRINGES
ASSESSING THE IMPACT ON DRUG DOSE DELIVERY OF A TWO-STEP AUTOINJECTOR
Isabelle Delcroix introduces a two-step autoinjector platform, Safelia, which incorporates innovative and patented design features that enable it to deliver a both fluid and viscous formulations from standard glass prefilled syringes.
RESPIRATORY
COMPANY SHOWCASE: NEMERA
In 2014, the healthcare business formerly known as Rexam Healthcare Devices became Nemera. This name change followed the May 2, 2014 acquisition by Montagu Private Equity.
Top